The Roles of Education and Patient Engagement to Improve Quality of Life for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia
The aim of the project is to ensure hematology care teams participating in new value- based reimbursement models have an accurate understanding of the evidence and roles of new therapies for relapsed/refractory CLL. In addition, hematology care teams will have access to best practice supportive care protocols to proactively assess, monitor, and manage symptoms to promote successful clinical outcomes. This project will lay the foundation for new supportive care delivery models incorporating professional education and patient engagement tools to improve clinical outcomes. We will collect real-world evidence to lay the foundation for predictive modeling of symptoms for the relapsed/refractory CLL patient population and evaluate the effectiveness of current evidence-based supportive care recommendations to improve QoL and mitigate ED visits/hospitalizations.
Impact of Electronic Treatment Planning on Shared Decision Making for HER2+ Metastatic Breast Cancer: An Educational/Research Initiative
Four cancer networks across the United States who are participating in the CMS’s Oncology Care Model (OCM) payment program will be selected to participate in this educational/research initiative. All organizations participating in the OCM program will be invited. At initiation, Carevive will work with these institutions and their population health vendor/data warehouses to better understand what are their providers’ metastatic breast cancer (MBC) practice patterns and adherence to evidence-based guidelines. Following the CME, the medical oncologists treating HER2+ MBC patients will use the Carevive software, which includes an electronic Patient-Reported Outcomes (e-PRO) platform for patients and treatment planning tools for clinicians. The Carevive software interfaces with most enterprise EHRs. Through the e-PRO platform, treating clinicians can better understand patients’ personalized needs that impact treatment planning.
Understanding Evidence-Based Practice Patterns in Advanced NSCLC: An Educational/Research Initiative in Mid-Atlantic States
The goals of this initiative are to close clinical knowledge and performance gaps by providing oncology clinicians with the latest advances and emerging research in the evidence-based and personalized treatment of advanced NSCLC patients. Also, the goal is to offer expert insights, IT infrastructure and clinical workflow processes to support cancer center’s need to meet quality measures relevant to value-based care delivery to patients with advanced NSCLC. We also hope to gain insights on clinician practice patterns related to advanced NSCLC, and the correlation between advanced NSCLC patients’ reported goals of care and advanced NSCLC patients’ fit/frailty status and treatment decisions.
Emerging Therapies and Clinical Trial Opportunities for ER-Positive, HER2-Negative Metastatic Breast Cancer and HER2-Positive Breast Cancer
The goals of this initiative are to close clinical knowledge and performance gaps by providing oncology clinicians with the latest advances and emerging research in ER-positive, HER2-negative metastatic breast cancer and HER2-positive breast cancer treatment; provide a mechanism for patients to receive personalized clinical trial care plans, and generate and disseminate data on clinician practice patterns relating to accrual to clinical trials (which patients and which trials) and patient interest in clinical trial participation. The ultimate goal is to show proof of concept that using the combination of certified training and patient care planning is an effective mechanism to help community oncologists better understand the evolving science, contribute to the sharing of clinical practice patterns, and help medical oncologists better engage and support their breast cancer patients interested in trial opportunities. These care plans offer comprehensive direction to patients, including education on their treatment, administration instructions, side effect management, surveillance, and cancer center referrals to and resources of the multidisciplinary team.
Integrating Touchscreen-based Geriatric Assessment and Frailty Screening for Adults with Multiple Myeloma to Drive Personalized Treatment Decisions
Primary aims of this multi-site study are to 1) evaluate the feasibility, acceptability, and usability of an abbreviated tablet-based geriatric assessment (GA) used at a treatment decision-making time point, 2) evaluate physician use of and perceived utility of the GA, including impact on treatment decision making, and 3) describe treatment decisions of hematologists managing older patients with MM, including differences by patient frailty status. The study will enroll approximately 120 older MM patients from across four cancer centers (30 patients per center). Patients will interact with the Carevive ePRO prior to a clinic visit in which a treatment decision is being discussed, and complete a streamlined GA, including only those items that have been shown most predictive of outcomes. These data will then be displayed back to the provider to be used at the point of care to help guide appropriate treatment assignment and potentially improve outcomes in older adults with MM. This study will serve as a first step and will lay the groundwork for a larger trial validating the abbreviated GA and its impact on treatment outcomes.
Achievement of National Quality Standards in Breast Cancer: A Pilot Study on the Impact of Certified Education Plus a Novel Care Planning Tool
The overall goal of this study is to evaluate the impact of the Carevive Care Planning System (CPS) technology and accredited continuing medical education on cancer center adherence to quality metrics relevant to the management of breast cancer patients (developed by ASCO and ONS). Five cancer centers will participate in the study with each site recruiting breast cancer patients. Clinicians will participate in the accredited continuing medical education and then, along with their respective patient participants, interact with the Carevive CPS™ during two visits, 6-weeks apart, with patients receiving a care plan at each visit. Provider’s patient-level adherence to 31 specific quality metrics will be evaluated by chart review at pre-test (baseline) and post-test (12 weeks), complemented by specific data extracted from the Carevive CPS platform.
Improving Clinical Trial Awareness in Non-Small Cell Lung Cancer: Pilot Testing a Novel Health Care Information Technology Platform Plus Certified Training at the Point of Care
The overall goal of the lung cancer trials study is to evaluate the impact of a novel individualized care planning/educational technology, the Carevive Care Planning System (CPS), on referral to clinical trials for recurrent or metastatic lung cancer, and patient and provider knowledge, attitudes, and beliefs about clinical trials. The study will enroll 30 patients per site over approximately six months, each of whom will participate in the CPS two-part intervention to consist of (1) clinician participation in certified training (CME) about the role of biomarkers in NSCLC treatment and new targeted and immunotherapy agents for NSCLC, and (2) use of the CPS at the point of care to identify clinical trial opportunities for patients with NSCLC interested in learning about trial participation as a treatment option, and providing personalized education to patients about trials for which they are eligible. Study outcomes will be evaluated at baseline and 6 weeks using questionnaires adapted from the literature.
Improving the Quality of Multiple Myeloma Treatment with Patient Care Plans: Pilot Testing the Impact of Certified Training and Care Planning on Symptom Management
The overall goal of the myeloma study is to evaluate the use of the Carevive Care Planning System (CPS) technology and certified training (CME) on supportive care and symptom management practices for individuals with myeloma receiving active treatment. Five cancer centers will participate in the study and will recruit 15-30 patients per site over a 6-month period. Each patient participant and his/her provider(s) will interact with the Carevive CPS during two visits, with patients receiving a personalized care plan at each visit.
Improving Surgical/Medical Oncology Collaboration for Breast Cancer Treatment Planning: Pilot Testing the Impact of Certified Training and Patient Care Planning
Neoadjuvant systemic therapy is vastly underutilized in eligible patients desiring breast conservation. Provider and institutional factors, such as provider knowledge and institutionally based care coordination networks, likely play large roles in influencing treatment patterns. In addition, patient factors such as distress and lack of information may cloud patient decision-making capabilities at this time. In this study, six cancer programs will accrue 35 newly diagnosed breast cancer patients to participate in a study over a 3-month period (n=105 breast cancer patients total). Patients will be recruited from surgical practices and will be referred to medical oncology, where they will receive a care plan that outlines initial treatment, as well as distress screening and management.